Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Cash from Discontinued Operations (2022)

Historic Cash from Discontinued Operations for Regenerative Medical Technology (RMTG) over the last 1 years, with Q4 2022 value amounting to $69463.0.

  • Regenerative Medical Technology's Cash from Discontinued Operations changed N/A to $69463.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $69713.0, marking a year-over-year change of. This contributed to the annual value of $69713.0 for FY2022, which is 62784.89% up from last year.
  • According to the latest figures from Q4 2022, Regenerative Medical Technology's Cash from Discontinued Operations is $69463.0.
  • In the past 5 years, Regenerative Medical Technology's Cash from Discontinued Operations ranged from a high of $69463.0 in Q4 2022 and a low of -$234.0 during Q3 2022